全球近视黄斑部病变市场：各地区及国家分析与预测（2025-2035）

由于高度近视盛行率上升、诊断和治疗方案的进步以及人口老化等因素，全球近视黄斑部病变市场正在经历显着增长。

随着近视性黄斑部病变治疗和介入需求的不断增长，该市场在改善视力丧失患者的治疗效果和维持其生活品质方面发挥关键作用。该市场涵盖诊断工具、治疗技术（例如抗VEGF疗法）以及管理视力丧失的辅助技术。

持续关注近视黄斑部病变的早期诊断、治疗和併发症管理，对于满足日益增加的近视患者的需求至关重要。认知度的提升、医疗基础设施的改善以及治疗方案的便利性，正在推动市场的成长。

在全球范围内，尤其是在都市区，近视发病率的上升与近视性黄斑部病变风险的增加直接相关，也是市场的主要成长要素之一。除了近视整体呈上升趋势外，高度近视的发生率也在上升。研究表明，高度近视患者数量的增长速度快于中度或轻度近视患者，预计到2050年，全球高度近视人口可能超过10亿。这种增长与近视性黄斑部病变病例数量的增加直接相关。

此外，抗血管内皮生长因子 (VEGF) 疗法的开发正在对近视黄斑部病变的治疗前景产生重大影响。这些治疗方法透过抑制视网膜内异常血管的生长来解决视力丧失的主要原因之一。新型抗 VEGF 疗法和联合治疗的核准正在提高治疗效果、改善治疗可及性并改善患者预后。

儘管存在这些积极的成长趋势，全球近视黄斑部病变市场仍面临许多挑战。主要挑战之一是高昂的治疗费用，这对许多患者，尤其是开发中国家和服务欠缺地区的患者，构成了巨大的医疗障碍。近视黄斑部病变病变治疗费用高昂，包括药物治疗和手术治疗，这往往使患者无法获得所需的护理，阻碍了市场成长。此外，由于与其他疾病的预算竞争，医疗保健系统难以拨出足够的资金来治疗近视黄斑部病变。

随着近视性黄斑部病变市场的不断发展，预计将在未来几年塑造市场动态的新兴趋势包括开发更具针对性和个性化的治疗方法、利用数位健康技术进行早期发现和后续观察，以及日益重视预防和患者教育。近视性黄斑部病变病变的盛行率不断上升，尤其是在老龄化人口和高度近视盛行率高的地区，预计将推动对更容易获得、更有效且更实惠的治疗方法的需求。此外，对创新药物、眼科给药装置开发和手术技术进步的投资不断增加，可能在未来几年为关键相关人员提供巨大的成长机会。

本报告调查了全球近视黄斑部病变市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章市场：产业展望

• 市场趋势
• 法律规范
• 近视黄斑部病变的流行病学
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

2. 全球近视黄斑部病变市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

3. 全球近视黄斑部病变市场：竞争格局与公司概况

• 关键发展和策略
  • M&A
  • 协同努力
  • 业务扩展和资金筹措
  • 产品发布和核准
  • 其他活动
• 公司简介
  • Regeneron Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Bayer AG.

第四章调查方法

Global Myopic Macular Degeneration Market, Analysis and Forecast: 2025-2035

The global myopic macular degeneration market is experiencing significant growth, primarily driven by the increasing prevalence of high myopia, advancements in diagnostic and therapeutic solutions, and a growing aging population. As demand for treatments and interventions for myopic macular degeneration rises, the market plays a crucial role in improving patient outcomes and maintaining the quality of life for individuals affected by vision impairment due to myopia-related complications. The myopic macular degeneration market encompasses diagnostic tools, therapeutic innovations like anti-VEGF therapies, and supportive technologies to manage vision loss.

The continued focus on early diagnosis, treatment, and managing complications from myopic macular degeneration is crucial in addressing the increasing number of individuals affected by this condition. Increased awareness, improved healthcare infrastructure, and enhanced accessibility to treatment options are fuelling the growth of this market.

One of the significant drivers of the global myopic macular degeneration market is the rising global incidence of myopia, particularly in urbanized regions, is directly contributes to a higher risk of developing myopic macular degeneration. Myopia in general is becoming more widespread, and the proportion of people developing high myopia is also on the rise. Research indicates that high myopia is growing more rapidly than moderate or low myopia, with estimates suggesting that the number of individuals with high myopia could increase to over 1 billion globally by 2050. This growing number directly correlates with a rise in myopic macular degeneration cases.

Moreover, the development of anti-vascular endothelial growth factor (VEGF) therapies has significantly impacted the treatment landscape for myopic macular degeneration. These therapies help in preventing the growth of abnormal blood vessels in the retina, addressing one of the key causes of vision loss in myopic macular degeneration. The approval of new anti-VEGF treatments and combination therapies enhances the effectiveness of interventions, making treatments more accessible and improving patient outcomes.

Despite the positive growth trajectory, several challenges continue to impact the global myopic macular degeneration market. One of the primary challenges is the high cost of treatments, which creates a barrier to accessibility for many patients, especially in developing countries or underserved regions. The high costs of both medication and surgeries related to myopic macular degeneration treatment can limit patient access, which in turn hampers the growth of the market. Healthcare systems are often challenged to allocate funds for myopic macular degeneration treatments, given the competitive pressures from other conditions that also demand funding.

Leading players in the global myopic macular degeneration market, such as Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, and Bayer AG, are continuously innovating to improve the effectiveness and comfort of myopic macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of myopic macular degeneration while enhancing their market positions globally.

The competitive landscape of the global myopic macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the myopic macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.

As the myopic macular degeneration (MMD) market continues to evolve, emerging trends such as the development of more targeted and personalized therapies, the increasing use of digital health technologies for early detection and monitoring, and the growing focus on prevention and patient education are expected to shape its future landscape. The rising prevalence of myopic macular degneration, especially in aging populations and regions with high myopia rates, will fuel demand for more accessible, effective, and affordable treatment options. Additionally, the increasing investment in innovative drug development, development of ophthalmic drug delivery devices, and surgical techniques will present significant growth opportunities for key stakeholders in the coming years.

In conclusion, the global myopic macular degeneration market is poised for steady growth, driven by advancements in treatment technologies, a growing awareness of the condition, and the ongoing efforts to enhance patient outcomes. As the need for specialized care increases, both global and regional players will continue to play a critical role in providing solutions to those affected by myopic macular degeneration, ultimately improving the quality of life for patients and ensuring better long-term eye health.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology of Myopic Macular Degeneration
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Myopic Macular Degeneration Market (Region), ($Million), 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Myopic Macular Degeneration Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Myopic Macular Degeneration Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Myopic Macular Degeneration Market, by Country
      • 2.3.3.1.1 Japan

3. Global Myopic Macular Degeneration Market: Competitive Landscape and Company Profiles

• 3.1 Key Development and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Regeneron Pharmaceuticals Inc.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 F. Hoffmann-La Roche Ltd
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Bayer AG.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Myopic Macular Degeneration Market, Dynamics Impact Analysis
• Figure: Epidemiology of Myopic Macular Degeneration
• Figure: Global Myopic Macular Degeneration Market Coverage
• Figure: Global Myopic Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Myopic Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Myopic Macular Degeneration Market, Clinical Trial Analysis,
• Table: Global Myopic Macular Degeneration Market Dynamics, Impact Analysis
• Table: Global Myopic Macular Degeneration Market (by Region), $Million, 2023-2035